Open AccessEfficacy of Ibrexafungerp (SCY-078) against Candida auris in an In Vivo Guinea Pig Cutaneous Infection Model
Author(s) -
Mahmoud A. Ghannoum,
N. Isham,
David Angulo,
Katyna Borroto–Esoda,
Stephen Barat,
Lisa Long
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00854-20
Subject(s) - candida auris , guinea pig , pharmacokinetics , in vivo , dosing , medicine , colonization , antibiotics , biology , dermatology , microbiology and biotechnology , antifungal
Candida auris has been shown to have a high risk of skin colonization in hospitalized patients, possibly contributing to nosocomial spread. In a guinea pig skin model, animals were evaluated for clinical appearance, tissue fungal burden, histology, and pharmacokinetics. Oral dosing with 10 mg/kg ibrexafungerp (IBX) reduced the severity of lesions and significantly reduced the C. auris fungal burden in infected animals compared with untreated controls. This indicates promise for use of IBX in controlling skin infection and colonization of hospitalized patients.